Who
Keith Lamont Cummings
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Pliant Therapeutics.
In numbers
- Trades disclosed
- 83
- Buys
- 0
- Sells
- 9
- Bought
- $0
- Sold
- $3.0M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 28 Feb 2020
- Last trade
- 17 Apr 2026
- Last filed
- 17 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —76,047 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —76,200 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —110,500 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,500 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —113,300 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —113,300 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —76,047 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —18,198 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —76,047 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —76,047 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —18,198 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,198 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —74,250 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —74,250 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —124,000 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —124,000 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —76,200 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —76,200 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —110,500 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,500 at $0.00 | filing |
News
Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA)PLRX · manilatimes.net · 20 Oct 2026
0 headlines in the last 90 days name Keith Lamont Cummings; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.